Bristol-Myers Squibb Company (NYSE:BMY) – Eliquis® (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
June 27, 2014 at 07:01 AM EDT
[Business Wire] – Bristol-Myers Squibb Company and Pfizer Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending that Eliquis . . . → Read More: Bristol-Myers Squibb Company (NYSE:BMY) – Eliquis® (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE Similar Articles: Stock Update (NYSE:BMY): Bristol-Myers Squibb Announces Dividend Company Update (NYSE:BMY): Bristol-Myers Squibb Ranks First on 2014 Best Corporate Citizens List Company Update – Bristol-Myers Squibb Company (NYSE:BMY) – Xigduo™ (dapagliflozin and metformin hydrochloride) receives positive CHMP opinion in the European Union for the treatment of type 2 diabetes